Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 29;9(3):660.
doi: 10.3390/jcm9030660.

Association between the Use of Dipeptidyl Peptidase 4 Inhibitors and the Risk of Dementia among Patients with Type 2 Diabetes in Taiwan

Kuan-Chan Chen  1 , Chi-Hsiang Chung  2 , Chieh-Hua Lu  1 , Nian-Sheng Tzeng  3   4 , Chien-Hsing Lee  1 , Sheng-Chiang Su  1 , Feng-Chih Kuo  1 , Jhih-Syuan Liu  1 , Chang-Hsun Hsieh  1 , Wu-Chien Chien  2   5   6
Affiliations

Association between the Use of Dipeptidyl Peptidase 4 Inhibitors and the Risk of Dementia among Patients with Type 2 Diabetes in Taiwan

Kuan-Chan Chen et al. J Clin Med. .

Abstract

Study objectives: Diabetes mellitus per se and its related therapy have been frequently associated with an increased risk of developing dementia. However, studies that explored the risk of dementia from the use of the novel oral antidiabetic medication dipeptidyl peptidase 4 inhibitor (DPP-4i) have been limited, especially in Asian populations. The present study aimed to determine the effect of DPP-4i on the subsequent risk of dementia among patients with type 2 diabetes (T2D) in Taiwan.

Methods: This study utilized data from the Longitudinal Health Insurance Database between 2008 and 2015. We enrolled 2903 patients aged ≥50 years, who were on DPP-4i for a diagnosis of T2D and had no dementia. A total of 11,612 subjects were included and compared with a propensity score-matched control group who did not use DPP-4i (non-DPP-4i group). Survival analysis was performed to estimate and compare the risk of dementia-including Alzheimer's disease, vascular dementia, and other dementia types-between the two groups. Results: Both groups had a mean age of 68 years, had a preponderance of women (61.8%), and were followed up for a mean duration of 7 years. The risk of all-cause dementia was significantly lower in the DPP-4i group than in the non-DPP-4i group (hazard ratio (HR) 0.798; 95% confidence interval (CI) 0.681-0.883; p < 0.001), with a class effect. This trend was particularly observed for vascular dementia (HR 0.575; 95% CI 0.404-0.681; p < 0.001), but not in Alzheimer's disease (HR 0.891; 95% CI 0.712-1.265; p = 0.297). The Kaplan-Meier analysis showed that the preventive effect on dementia was positively correlated with the cumulative dose of DPP-4i. Conclusions: DPP-4i decreased the risk of dementia with a class effect, especially vascular dementia, but not in Alzheimer's disease. Our results provide important information on the drug choice when managing patients with T2D in clinical practice.

Keywords: DPP-4 inhibitor; alzheimer’s disease; dementia; diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
A flow chart of the sample selection process. DM = diabetes mellitus; DPP-4i = dipeptidyl peptidase 4 inhibitor; GLP-1 agonist = glucagon-like peptide 1 agonist; OHA = Oral Hypoglycemic Agents.
Figure 2
Figure 2
Kaplan–Meier curves for the cumulative risk of dementia in diabetic patients with or without dipeptidyl peptidase 4 inhibitor use.
See this image and copyright information in PMC

References

    1. DAROC Clinical Practice Guidelines for Diabetes Care- 2018. Diabetes Association of the R.O.C.; Taipei, Taiwan: 2018. p. 19. - PubMed
    1. Sun Y., Lee H.J., Yang S.C., Chen T.F., Lin K.N., Lin C.C., Wang P.N., Tang L.Y., Chiu M.J. A nationwide survey of mild cognitive impairment and dementia, including very mild dementia, in Taiwan. PLoS ONE. 2014;9:e100303. doi: 10.1371/journal.pone.0100303. - DOI - PMC - PubMed
    1. Tzeng N.S., Chang C.W., Hsu J.Y., Chou Y.C., Chang H.A., Kao Y.C. Caregiver Burden for Patients with Dementia with or Without Hiring Foreign Health Aides: A Cross-Sectional Study in a Northern Taiwan Memory Clinic. J. Med. Sci. 2015;35:239–247. doi: 10.4103/1011-4564.172999. - DOI
    1. Wang H.Y., Chen J.H., Huang S.Y., Yeh H.W., Mao W.C., Chang H.A., Kao Y.C., Yeh C.B., Chou Y.C., Chiang W.S., et al. Forensic evaluations for offenders with dementia in Taiwan’s criminal courts. J. Am. Acad. Psychiatry Law. 2018;46:45–51. in press. - PubMed
    1. Tzeng N.S., Chiang W.S., Chen S.Y., Chou Y.C., Lee K.M., Huang S.Y., Yeh C.B., Chen C.Y., Chang H.A., Kao Y.C. The Impact of Pharmacological Treatments on Cognitive Function and Severity of Behavioral Symptoms in Geriatric Elder Patients with Dementia. Taiwan. J. Psychiatry (Taipei) 2017;31:69–79.

LinkOut - more resources